Praxis Precision Medicines Files 8-K
Ticker: PRAX · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1689548
| Field | Detail |
|---|---|
| Company | Praxis Precision Medicines, Inc. (PRAX) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $250 million, $86.2 million, $250 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
Praxis Precision Medicines filed an 8-K on Sept 2nd, likely with financial updates or other material events.
AI Summary
On September 2, 2025, Praxis Precision Medicines, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided text excerpt.
Why It Matters
This 8-K filing signals that Praxis Precision Medicines has made a significant disclosure to the SEC, potentially impacting investor understanding of the company's current status or future plans.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific operational, financial, or strategic information that would indicate a high-risk event.
Key Players & Entities
- Praxis Precision Medicines, Inc. (company) — Registrant
- 001-39620 (company) — Commission File Number
- 47-5195942 (company) — I.R.S. Employer Identification No.
- September 2, 2025 (date) — Date of earliest event reported
- Boston, Massachusetts (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering "Other Events" and "Financial Statements and Exhibits."
When was the earliest event reported in this filing?
The earliest event reported is dated September 2, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Praxis Precision Medicines, Inc.
In which state was Praxis Precision Medicines, Inc. incorporated?
Praxis Precision Medicines, Inc. was incorporated in Delaware.
What is the principal executive office address of Praxis Precision Medicines, Inc.?
The address of the principal executive offices is 99 High Street, 30th Floor, Boston, Massachusetts 02110.
Filing Stats: 1,239 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2025-09-05 16:48:14
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value per share PRAX The Nasdaq
- $250 million — ng an aggregate offering price of up to $250 million from time to time through Jefferies, ac
- $86.2 million — gregate gross proceeds of approximately $86.2 million. As a result of the termination of the
- $250 m — th an aggregate offering price of up to $250 million, from time to time, through an "a
Filing Documents
- tm2525240d2_8k.htm (8-K) — 35KB
- tm2525240d2_ex1-1.htm (EX-1.1) — 214KB
- tm2525240d2_ex5-1.htm (EX-5.1) — 15KB
- tm2525240d2_ex5-1img001.jpg (GRAPHIC) — 4KB
- tm2525240d2_ex5-1img002.jpg (GRAPHIC) — 2KB
- 0001104659-25-087865.txt ( ) — 499KB
- prax-20250902.xsd (EX-101.SCH) — 3KB
- prax-20250902_lab.xml (EX-101.LAB) — 33KB
- prax-20250902_pre.xml (EX-101.PRE) — 22KB
- tm2525240d2_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. Termination of 2024 Sales Agreement As previously disclosed, on March 5, 2024, Praxis Precision Medicines, Inc. (the "Company") entered into an Open Market Sale Agreement SM (the "Original 2024 Sales Agreement") with Jefferies LLC ("Jefferies"), and on December 23, 2024, entered into Amendment No. 1 to the Original 2024 Sales Agreement (the "2024 Sales Agreement Amendment", and together with the Original 2024 Sales Agreement, the "2024 Sales Agreement") with Jefferies, pursuant to which the Company could offer and sell shares of its common stock, par value $0.0001 per share (the "Common Stock"), having an aggregate offering price of up to $250 million from time to time through Jefferies, acting as the sales agent (the "2024 ATM Program"). On September 2, 2025, the Company delivered written notice to Jefferies to terminate the 2024 Sales Agreement pursuant to Section 7(b) thereof, effective immediately. The Company is not Company has sold an aggregate of 1,368,176 shares of Common Stock for aggregate gross proceeds of approximately $86.2 million. As a result of the termination of the 2024 Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the 2024 ATM Program. A copy of each of the Original 2024 Sales Agreement and the 2024 Sales Agreement Amendment were filed as Exhibit 1.2 and Exhibit 1.3, respectively, to the Company's shelf registration statement on Form S-3ASR (File No. 333-284016) filed with the Securities and Exchange Commission (the "Commission") on December 23, 2024 and became immediately effective upon filing (the "Registration Statement"). The description of the 2024 Sales Agreement contained in this Current Report on Form 8-K does not purport to be complete and is qualified in its entirety by reference to the copy of each of the Original 2024 Sales
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Exhibit Description 1.1 Sales Agreement, dated as of September 5, 2025, between Praxis Precision Medicines, Inc. and TD Securities (USA) LLC. 5.1 Opinion of Latham & Watkins, LLP. 23.1 Consent of Latham & Watkins, LLP (included in Exhibit 5.1).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRAXIS PRECISION MEDICINES, INC. Date: September 5, 2025 By: /s/ Marcio Souza Marcio Souza Chief Executive Officer